WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?

The standard of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is androgen deprivation therapy (ADT) with docetaxel or abiraterone. However, numerous retrospective studies suggested outcome benefit of prostate radiotherapy. Small randomized trial (HORRAD) showed no overall surviva...

Descripción completa

Detalles Bibliográficos
Autor principal: Bišof, Vesna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693553/
https://www.ncbi.nlm.nih.gov/pubmed/34975196
http://dx.doi.org/10.20471/acc.2019.58.s2.06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693553/
https://www.ncbi.nlm.nih.gov/pubmed/34975196
http://dx.doi.org/10.20471/acc.2019.58.s2.06

Ejemplares similares